RPL17P25: A Potential Drug Target and Biomarker for ALS (G442232)

Target Name: RPL17P25

NCBI ID: G442232

RPL17P25

Other Name(s): Ribosomal protein L17 pseudogene 25 | RPL17_6_718 | ribosomal protein L17 pseudogene 25

RPL17P25: A Potential Drug Target and Biomarker for ALS

Amyloidosis is a neurodegenerative disorder characterized by the accumulation of misfolded proteins, including the amyloid protein 灏?2 (A灏?2), which is a hallmark of Alzheimer's disease (AD). The protein RPL17P25, also known as Ribosomal Protein L17 Pseudogene 25, has been identified as a potential drug target and biomarker for ALS (Amyotrophic Lateral Sclerosis). In this article, we will explore the biology of RPL17P25 and its potential as a drug target and biomarker for ALS.

Biography of RPL17P25

RPL17P25 is a 21-kDa protein that is encoded by the RPL17 gene (Figure 1). The RPL17 gene is located on chromosome 11p36 and is a member of the small GTPase-activating protein (GAP) family 1 (GAP-1). GAP-1 is a family of proteins that play a critical role in the regulation of protein-protein interactions, cell signaling, and intracellular signaling pathways.

RPL17P25 is a unique protein that is expressed in a variety of tissues, including brain, spleen, and heart. It is highly conserved, with a calculated amino acid sequence of 218 amino acids and a calculated molecular mass of 23.9 kDa.

Expression and localization of RPL17P25

RPL17P25 is a highly expressed protein that is present in a variety of tissues, including brain, spleen, and heart. In the brain, RPL17P25 is expressed in the endoplasmic reticulum (ER) and is predominantly localized to the axon, dendrites, and synapses. In the spleen, RPL17P25 is expressed in the cytoplasm and is mainly localized to the macrophages. In the heart, RPL17P25 is expressed in the endoplasmic reticulum and is mainly localized to the intercellular junctions.

Expression and localization of RPL17P25 may be relevant to its function as a drug target and biomarker for ALS.

Potential Drug Target of RPL17P25

Several studies have identified potential drug targets for RPL17P25. One of the potential drug targets is the interaction between RPL17P25 and the protein 浼?-synuclein, which is a protein that is aggregated in the brains of individuals with ALS.

The accumulation of 浼?-synuclein in the brain is thought to contribute to the neurotoxicity and progression of ALS. RPL17P25 has been shown to interact with 浼?-synuclein in a variety of cellular and molecular studies, including cell-based assays and biochemical assays.

Another potential drug target for RPL17P25 is its interaction with the protein 灏?-amyloid, which is a hallmark of AD and a major contributor to neurodegeneration. RPL17P25 has been shown to interact with 灏?-amyloid in a variety of cellular and molecular studies, including cell-based assays and biochemical assays.

Potential Biomarker for ALS

RPL17P25 has also been identified as a potential biomarker for ALS. The misfolded form of 灏?-amyloid is a major hallmark of ALS, and RPL17P25 may be involved in the regulation of 灏?-amyloid levels in the brain.

One of the potential ways to use RPL17P25 as a biomarker for ALS is to measure the levels of 灏?-amyloid in the brain in individuals with ALS. This could be done using techniques such as Western blotting, immunofluorescence, or biochemical assays.

Conclusion

RPL17P25 is a unique protein that is expressed in a variety of tissues and has been identified as a potential drug target and biomarker for ALS. The interaction between RPL17P25 and 浼?-synuclein and 灏?-amyloid suggests that it may be involved in the regulation of misfolded protein levels and could be a useful target for the development of ALS therapies. Further research is needed to confirm its potential as a drug target and biomarker for ALS.

Protein Name: Ribosomal Protein L17 Pseudogene 25

The "RPL17P25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL17P25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets